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ABSTRACT
Objective: Azadirachta indica is a treasure of multiple pharmacological properties and presently leaves of this plant have been explored to evaluate 
the neuroprotective potential in diabetic rats.
Methods: Male Sprague-Dawley rats were injected with single intra peritoneal dose of streptozotocin (STZ) (60 mg/kg body weight [BW]) to develop 
animal model of diabetes. Post 21 days of STZ induction, animals were treated with aqueous A. indica leaf extract (ALE, 600 mg/kg BW) for seven 
consecutive days. Followed this, all animals were evaluated for the levels of blood glucose, lipid peroxidation (LPO), C-reactive proteins (CRP), pro-
oxidant biomarkers and histological changes.
Results: STZ treated rats exhibited elevated levels of blood glucose, LPO, CRP, and altered pro-oxidant biomarkers in comparison to control rats. 
Besides this, histological alterations/damage was evidenced as fragmentation, vacuolization, inflammation, etc. However, ALE treatment to these 
rats significantly decreased blood glucose levels, LPO, CRP levels, and restored pro-oxidants status. Light microscopic and ultramicroscopic analysis 
also indicated less damage, tissue architectural changes in comparison to untreated diabetic rats. Further, decrease in hyperalgesia and inflammation 
levels along with protective and restorative changes following ALE treatment suggested the neuroprotective potential of A. indica leaves in diabetic 
rats.
Conclusion: The oral administration of ALE to STZ induced diabetic animals resulted in neuroprotection against degenerative oxidative stress 
associated with metabolic and histopathological damage in the brain.
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INTRODUCTION
Diabetic neuropathy has become a major concern during the past few 
years, as it is the most common and troublesome form of complication 
leading to higher hospitalization rate if compared to other diabetic 
complications [1]. Approximately, 50-60% of patients with long-
standing diabetes have been documented to develop chronic or 
acute neurological complications [2-4]. Hyperglycemia is the major 
driving force that leads to functional as well as structural damage 
to a variety of organs including nervous system. Various metabolic 
pathways are associated with the development and progression of 
diabetic neuropathy and neurodegeneration [5]. Thus, alternations in 
the metabolic pathways may result in damaged mitochondria leading 
to increased production of reactive oxygen species and impaired 
antioxidant associated immunity [3,6-8]. Pathological changes such 
as vascular alterations, disturbed synaptic plasticity, and alteration in 
neurotransmission have been reported in diabetic neuropathy [6,9]. 
Besides this, other neuropathological changes including damage 
to neurons, Schwann cells, axons and inflammation have also 
been reported in several diabetic cases [10]. Thus, poor control or 
uncontrolled hyperglycemia is an important factor responsible for the 
late-stage neural complications and inflammation in the brain which 
further increase the levels of inflammatory markers such as C-reactive 
proteins (CRP) in the tissue as well in the blood [11].
The current treatment methods of diabetes include chemical drugs 
and insulin injections; most of the treatment methods are not user-
friendly and sometime associated with side effects. For instance, 
the invasive process of insulin injections exposes the patients to 
high risk of premature atherosclerosis, hypoglycemic episodes, 
lipodystrophy [12]. Sulfonylureas and lidocaine may are effective in 
ameliorating neuropathic pain, but they have reported debilitating 
side effects [9]. On the other hand, plants and their extracts are easily 
available, efficacious, cost-effective, and considered less toxic. World 
Health Organization has also recommended the usage of herbal drugs 
for treating various diseases in developing countries [13].
Azadirachta indica (neem) is very important among the herbal medicinal 
treasure due to its long list of associated medicinal properties [6,14]. 
All parts of A. indica are used in the treatment of various diseases 
such as malaria fever, tooth decay, ulcers, liver infections, diarrhea, 
and diabetes. [14,15]. It is widely used in soaps, detergents, and 
pest control management systems [16]. The hydroalcoholic extracts, 
aqueous extracts, crude ethanol extracts, and petroleum ether extract 
of A. indica have been reported to have blood glucose lowering effect 
in several animal models including diabetic rats, dogs, rabbits, and 
mice [6,12]. Thus, based on this knowledge and considering the 
pharmacological properties of A. indica, the leaves of this plant are 
used in this study to evaluate the antioxidative and tissue protective 
potential in streptozotocin (STZ) induced diabetic rats.
METHODS
Chemicals
All the chemicals used in the study were of analytical grade. STZ was 
procured from Hi Media (Mumbai, India). Glutathione reductase (GRx), 
purchased from Sigma (St. Louis MO, USA). CRP, ELISA kit (Affymetrix 
eBiosciences, Santa Clara, CA, USA).
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Preparation of aqueous A. indica leaf extracts (ALE) and dose 
selection
The leaves of A. indica were collected from botanical garden of Panjab 
University (PU), Chandigarh, and duly certified by National Institute 
of Science Communication and Information Resources, New Delhi, 
India. The aqueous extract was prepared according to the method of 
Hussein [17], by taking fresh leaves of A. indica (200 g) and grinded 
in 1 L of double distilled water, and suspension was filtered through 
Whatman filter paper no 1. The filtrate was lyophilized to obtain 
powder extract. Everyday required quantity of powder extract was 
dissolved in distilled water to prepare a fresh dose of ALE (600 mg/kg 
body weight [BW]) and dose was selected on the basis of our previously 
published study [18].
Animal models of diabetes
Healthy male Sprague-Dawley rats weighing 160±10 g were obtained 
from Central Animal House PU, Chandigarh, and housed in the 
polypropylene cages at ambient temperature with 12 hrs dark and 
12 hrs light cycle. Animals were fed on standard pellet diet with free 
access to water. All procedures and treatment were duly approved 
by the Animal Ethics Committee (CPCSEA) of P. U. Chandigarh 
(IAEC/346-356 dated 11.2.2013).
After 1 week of acclimatization to laboratory conditions, animals were 
randomly divided into three groups, Group 1 - Control, Group 2 - Diabetic, 
and Group 3 - Diabetic treated with ALE (D+ALE). Each group had six 
animals. Animals of Group 2 and Group 3 were induced diabetes by 
a single intraperitoneal injection of STZ (60 mg/kg BW.) prepared 
in saline solution [19]. Post STZ induction (72 hrs), diabetes was 
established (fasting blood glucose level ≥250 mg/dl) in Group 2 and 
Group 3 animals.
All animal groups were kept under observation for 21 days following 
STZ treatment. After this, animals of Group 3 were treated with an 
oral dose of ALE (600 mg/kg BW. volume 0.5 ml), while the animals 
in Group 1 and Group 2 received the same volume of distilled 
water once in a day for next 7 days. After 28 days, all animals were 
sacrificed under mild ether anesthesia, brain tissues were isolated, 
and blood was collected in clean test tubes. The brain tissues were 
homogenized (10% w/v) in 0.1 M Tris HCl buffer (pH 7.4) to prepare 
post-mitochondrial supernatant (PMS), and blood was centrifuged to 
prepare plasma.
Antioxidant profile
Antioxidants analysis was performed in PMS using standard methods. 
The activity of catalase CAT was measured using the method of 
Luck [20]. The activity GRx was assayed by the method of Carlberg 
and Mannervik [21]. The activity of glutathione peroxidase (GPx) 
was measured by the method of Flohé and Gunzler [22]. Superoxide 
dismutase (SOD) activity was determined by the method of Kono [23]. 
Reduced glutathione (GSH) was measured by the method of Ellman [24] 
and lipid peroxidation (LPO) by the method of Wills [25]. Protein 
content was estimated by the method of Lowry et al. [26]. Blood 
glucose levels were estimated using Glucometer, Abbott Labs Ltd. The 
optical density of all biochemical estimations was read on Shimadzu 
ultraviolet-visible spectrophotometer 1240.
Histological analysis
The study was conducted using light microscopic (LM) and transmission 
electron microscopic examination (TEM). For LM brain (cerebral cortex) 
was fixed in formalin saline and washed with distilled water. Then, 
tissues were processed through different percentages of alcohol and 
cleared through xylene treatment. Finally, thin sections of 5-6 µm were 
cut and stained with hematoxylin and eosin stain and viewed under light 
microscope. However, for TEM very thin sections of the brain (cerebral 
cortex) were cut and fixed in Karnowsky fixative (Glutaraldehyde based 
fixative). Dehydration and clearing steps were performed with acetone 
and toluene, respectively. Sections were embedded using liquid Araldite 
and ultrathin sections (60-80 nm) were cut with special microtome 
followed by staining and viewed under TEM (Morgagni 268D) at AIIMS, 
New Delhi.
Estimation of CRP
The levels of CRP in blood plasma were estimated using commercially 
available ELISA kit.
Behavior studies
The behavior studies were conducted to evaluate the pain perception 
and hyperalgesia using hot plate test and tail immersion test. Hot 
plate test was performed according to the method of Woolfe and 
MacDonald [27] while tail immersion test was performed according to 
the method of Ben-Bassat [28].
Statistical analysis
All observations including nonceptive thresholds were expressed as 
mean±standard error of mean for six animals and variation in the data 
was analyzed using one-way analysis of variance followed by LSD post-
hoc test using SPSS software version 16.0. The p≤0.05 was considered 
statistically significant.
RESULTS
Blood glucose and BW
STZ is a routinely used diabetogen to induce diabetes in animals. In 
this study, Group 2 and Group 3 animals developed hyperglycemia 
(≥250 mg/dl) on the 3rd day of STZ injection. The blood glucose levels 
in these animals were found to be significantly high (p≤0.001) in 
comparison to control animals. However, the oral administration of ALE 
significantly reduced blood glucose levels (~55%) in Group 3 animals 
(Fig. 1), as compared to Group 2 animals. On the other hand, STZ treated 
animals reflected a significant reduction (p≤0.001) in their BWs, 
i.e., both Group 2 and Group 3 animals. However, in Group 2 animals 
the decrease in BW remained continues till the end of experimental 
period (28th day), while in Group 3 animals the decrease in BW was 
prevented with ALE treatment (Fig. 2). In totality, the Group 2 animals 
reduced ~9 g of their BW while the Group 3 animals reduced ~2.2 g of 
their BWs during the 7 days treatment period (21st to 28th day).
Antioxidants profile
The STZ treated rats showed significant changes in their antioxidant 
parameters in comparison to control animals. Fig. 3 illustrates the 
antioxidant profile in diabetic rats, where the LPO levels were found 
to be increased by ~65%, and GSH levels decreased by ~25.4% in 
comparison to control rats. However, on ALE treatments to diabetic 
rats, the levels of LPO were found to be decreased by ~31%, and levels 
of GSH increased by ~18.5% in comparison to untreated diabetic rats 
(Group 2 animals). Thus, ALE treatment significantly decreased LPO 
(p≤0.001) and improved GSH levels (p≤0.001) in Group 3 animals. 
The change in the activities of various antioxidant enzymes CAT, SOD, 
GPx, and GRx illustrated in Fig. 3. Diabetic rats exhibited a significant 
Fig. 1: Blood glucose profile during Azadirachta indica leaf 
extract (ALE) treatment. D+ALE: Diabetes treated with A. indica 
leaf extract. All the values are expressed as mean ± SEM, n=6. 
Statistically significant difference from control a1p≤0.001 . 
Statistically significantly difference from diabetic b1p≤0.001
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increase in the activities of CAT, SOD, and GPx as ~191.8%, ~127.7%, 
and ~36.7%, respectively, while the activity of GRx was found to be 
decreased by ~28% in comparison to controls. The ALE treatment 
to Group 3 animals restored these enzymes activities toward control 
levels as ~33.2%, ~51.3%, ~27.1%, and ~25%, respectively, for CAT, 
SOD, GPx, and GRx enzymes. Thus, the ALE treatment improved the 
antioxidant profile in Group 3 animals.
Histological analysis
Fig. 4 represents the results of LM examination (Fig. 4a-c) and 
TEM (Fig. 4d-f) analysis of control, diabetic, and D+ALE brains, 
Fig. 2: Change in body weight during diabetes and Azadirachta 
indica leaf extract (ALE) treatment. D+ALE: Diabetic treated 
with A. indica leaf extract. All the values are expressed as 
mean±standard error of mean, n=6. Statistically significant 
difference from control a1p≤0.001
Fig. 3: Evaluation of antioxidant profile in the brain tissue of three groups of animals. (a) lipid peroxidation levels expressed as 
nmoles malondialdehyde formed/min/mg protein (b) glutathione (GSH) levels expressed as nmoles/mg protein (c) catalase activity 
expressed as µmoles hydrogen peroxide H2O2 decomposed/min/mg protein (d) superoxide dismutase activity expressed as enzyme 
units/mg protein where one unit of enzyme is the amount of enzyme inhibiting the rate of reaction (nitro blue tetrazolium reduction) by 
50%. (e) Glutathione peroxidase activity expressed as nmoles nicotinamide adenine dinucleotide phosphate (NADPH) oxidized/min/mg 
protein (f) glutathione reductase activity expressed as nmoles NADPH oxidized/min/mg protein. D+ALE: Diabetes treated with 
Azadirachta indica leaf extract. GSH reduced. All the values are expressed as mean±standard error of mean, n=6. Statistically significant 
difference from control a1p≤0.001, a2p≤0.01. The statistically significantly difference from diabetic b1p≤0.001, b2p≤0.01, b3p≤0.05. 





respectively (cerebral cortex). The control brain showed (Fig. 4a) 
normocytic neurons, few blood vessels, normal neuronal density, and 
compact arrangement of tissue. Morphologically most of the neurons 
appeared round or oval in shape. Similarly, at ultrastructural level, the 
tissue architecture in control animals (Fig. 4d) was found to be well 
maintained, without any morphological changes in mitochondrial 
structure and other organelles. However, the section taken from diabetic 
brain (Fig. 4b) revealed degenerative changes (red arrows), necrotic 
cells that indicated necrosis. Besides this, vacuolization, fragmentation, 
and alteration in the morphology of some of the neurons were also 
observed. The ultrastructural analysis of such untreated diabetic brains 
(Fig. 4e) reflected swollen or deformed mitochondria and appearance of 
myelination was also recorded.The analysis of the sections taken from 
D+ALE treated rats showed improvement in the morphology of neurons 
and tissue compactness. The ALE treated rats also revealed decrease 
in the necrotic cells and fragmentation in comparison to untreated 
diabetic rats. Further vacuolization around the neurons was found 
to be decreased. The ultrastructural analysis (Fig. 4f) demonstrated 
considerably deceased in the mitochondrial swelling and inflammation. 
The overall structural integrity was found to be improved in D+ALE 
animals in comparison to untreated diabetic animals.
Inflammatory markers
Fig. 5 represents the analysis of CRP in all the three groups of animals. 
The diabetic animals showed significantly (p≤0.001) elevated levels 
of CRP (~97%) with respect to control animals. The ALE treatment to 
diabetic rats significantly reduced (p≤0.001) these elevated levels and 
brought them toward control levels.
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Behavior analysis
Hyperalgesia was evaluated by performing tail immersion and hot plate 
tests. Fig. 6a demonstrates the results of hot plate test, where diabetic 
rats were observed to have ~61% lower pain threshold, i.e., low 
reaction time as compared to control rats. However, ALE treatment 
to diabetic rats improved pain threshold and observed to have ~33% 
with respect to control animals. Thus, a significant decrease in the pain 
threshold was observed in diabetic rats (p≤0.001) and ALE treatment 
reversed the same significantly (p≤0.001) toward control levels.
Similarly, Fig. 6b demonstrates the analysis of thermal hyperalgesia 
through tail immersion test where diabetic rats were observed to 
have ~58% decrease in pain threshold (reaction time increased) as 
compared to control rats. However, after ALE treatment, the pain 
threshold was observed to have decreased ~27.08% with respect 
to controls. Thus, the oral administration of ALE to diabetic rats 
significantly improved reaction time (p≤0.001) in comparison to 
untreated diabetic rats.
DISCUSSION
Diabetic neuropathy is the most perilous complication associated with 
sensory neurons, motor neurons, and structural alterations in the 
nervous tissue [1]. STZ induced diabetic models are the most accepted 
animal models of diabetic neuropathy owing to their reproducibility 
and irreversible diabetes [29,30]. The mechanism of STZ action involved 
alkylation and fragmentation of beta cells DNA. Similar results were 
observed in this study with the development of hyperglycemia post 
3 days of STZ induction in Group 2 animals. Besides this, the parallel 
reduction in the BWs of diabetic animals was also observed, which 
could be due to the over breakdown of stored glycogen and fat under 
the increased metabolic demand, during hyperglycemic state [31]. 
However, on ALE treatment, the Group 3 animals showed a remarkable 
reduction in their blood glucose levels and partially prevented weight 
loss. According to the previous reports, ALE is a concoction of many 
polyphenols and antioxidants compounds [12,32,33]. Most of these 
compounds are associated with the peripheral utilization of glucose, 
which might have resulted in lowering of blood glucose levels in 
Group 3 animals. Further, the blood glucose lowering effect of ALE may 
have inhibited the degradation of structural proteins which in turn 
prevented the weight loss in D+ALE animals [34,35].
Hyperglycemia affects the pro-oxidant state of the tissue. Oxidative 
stress and neuroinflammation combined with decline in antioxidative 
defense potential have been documented as the key pathophysiological 
mechanism, involved in various complications including diabetic 
neuropathy [3,7,36]. In this study, the activities of various antioxidant 
enzymes, viz., CAT, SOD, GRx, and GPx had been found to be modulated 
in diabetic animals. The hyper activities of CAT and SOD could be a 
response of overproduction of H2O2 and free radicals in the diabetic 
brain. The significant difference in the activities of various biomarkers 
in diabetic versus control animals indicated the augmented oxidative 
stress and tissue response during diabetes. Moreover, nervous tissue is 
considered to be rich in polyunsaturated fatty acids mainly arachidonic 
acid and docosahexaenoic acids which are highly sensitive to LPO and 
depleted antioxidant status [3,37]. The diabetic animals exhibited the 
similar biochemical imbalance in terms of increased LPO levels and 
decreased GSH levels. Hence, these levels revealed the magnitude of 
oxidative stress and extent of structural and functional damage to the 
nervous system.
During oxidative stress, many reactive molecules crosstalk and 
augment the delirious effect by causing alterations in the tissue 
architecture. However, the effect of LPO has widely been reported in 
the neural degeneration in various diseases including Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, amyotrophic 
lateral sclerosis, and Down syndrome [38]. In this study, LM and 
ultrastructural analysis reported significant changes in the tissue 
architectural and compactness indicated deteriorated condition of 
nervous tissue during hyperglycemia. Further decrease in neuronal 
density, neuromorphological changes and axonal sheath changes 
indicated neuronal injury and brain damage in diabetic animals. The 
observation of swelling of mitochondria or deformed mitochondria 
in diabetic brain substantiated the findings of light microscopy and 
pointed out the critical role of this organelle in diabetes. In addition, 
less availability of GSH and elevated levels of LPO in the diabetic state 
might have also caused the structural damage and developed neuronal 
alterations [39]. However, decreased levels of LPO and increased 
levels of GSH with ALE treatment improved the tissue architecture 
and reduced the neuropathological complication in Group 3 animals 
indicated a protective role of ALE.
Further, the observation of inflammation in diabetic brain suggested the 
neuronal injury and development of neuropathy. Kuhard et al. reported 
the inflammation in brain tissue of STZ treated animals [40]. Earlier 
inflammation was thought to be a part of Type II diabetes, but recently 
Fig. 5: Analysis of C-reactive proteins levels. Concentration 
expressed as ng/ml of plasma. D+ALE: Diabetes treated with 
Azadirachta indica leaf extract. All the values are expressed 
as mean±standard error of mean, n=6. Statistically significant 
difference from control a1p≤0.001, a2p≤0.01, a3p≤0.05. Satistically 
significantly difference from diabetic b1p≤0.001. Statistically 
significantly difference from D+ALE c1p≤0.001.
Fig. 4: Histological analysis of brain. Sections a-c represent light 
microscopic examination, and section d-f represent transmission 
electron microscopy examination. D+ALE: Diabetic rats 
treated with Azadirachta indica leaf extract, M: Mitochondria, 
MS: Myelin sheath, BV: Blood vessels, CA: Compact arrangement, 
Fr: Fragmentation, N: Neuron, NC: Necrotic cells. Black and white 
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inflammation has been considered as an important component of Type I 
diabetes and included as parameters in diabetes diagnosis [41,42]. CRP 
is another important marker of acute phase inflammation and well 
reported in diabetic patients as well as in diabetic animals [43,44]. The 
observation of elevated levels of CRP in diabetic animals confirmed the 
inflammation in the brain tissue and corroborated the histopathological 
findings. However, A. indica is considered as a rich source of natural 
products, viz., azadirachtin, nimbin, quercetin, gallic acid catechin, 
epicatechin and salannin [45] and most of these natural products have 
been reported to be useful in reducing inflammation [46,47]. Hence, the 
natural antioxidants of ALE might have reduced the inflammation and 
reversed the CRP levels in Group 3 animals.
Neuropathic pain or hyperalgesia is a manifestation of diabetic 
neuropathy [48]. Several studies have reported oversensitivity 
(feeling of excessive pain) in diabetic patients and animals [49-51]. 
Presently, diabetic animals exhibited decrease in threshold for 
pain perception and reported hyperalgesia. Hyperalgesia develops 
mainly due to local metabolic and microvascular changes in the 
nervous tissue [48]. The involvement of superoxide, peroxynitrite 
and hydroxyl radicals has already been well established in various 
animal models of hyperalgesia [52]. Besides this, the role of cytokines 
and inflammatory markers cannot be ignored in neuropathic pain 
and diabetic complications [53,54]. The results of this study also 
revealed metabolic changes and variation in the antioxidant profile 
of diabetic animals. Thus, alterations in the biochemical parameters 
seem to be akin with the microangiopathic effects which suggested 
the development of hyperalgesia in diabetic animals. However, the 
ALE treatment decreased neuronal inflammation, LPO, increased GSH 
content; suggested reduction in neuronal stress levels hence attenuated 
the hyperalgesia.
Thus in totality, this study suggests the oral administration of 
ALE to STZ induced diabetic animals resulted in neuroprotection 
against degenerative oxidative stress associated with metabolic and 
histopathological changes.
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